These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 1781036)
1. Evaluation of the circulating glycoprotein CA549 in mammary cancer and other malignancies. Clocchiatti L; De Biasi F; Cartei G; Sibau A; Vigevani E; Signor M; Giovannoni M; Ceschia V; Di Chiara F; Grandis S Tumori; 1991 Oct; 77(5):395-8. PubMed ID: 1781036 [TBL] [Abstract][Full Text] [Related]
2. Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA. Gion M; Plebani M; Mione R; Penzo C; Meo S; Burlina A Br J Cancer; 1994 Apr; 69(4):721-5. PubMed ID: 8142260 [TBL] [Abstract][Full Text] [Related]
3. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients. Nicolini A; Ferdeghini M; Colombini C; Carpi A J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796 [TBL] [Abstract][Full Text] [Related]
5. [Basic study of CA549, a new tumor marker for breast cancer, and evaluation of its clinical usefulness]. Yamaguchi A; Ushigome M; Imai T; Otake H; Igarashi H; Hatori N; Tomiyoshi K; Inoue T; Endo K Kaku Igaku; 1993 Mar; 30(3):317-22. PubMed ID: 8479100 [TBL] [Abstract][Full Text] [Related]
6. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912 [TBL] [Abstract][Full Text] [Related]
7. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Safi F; Kohler I; Röttinger E; Beger H Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278 [TBL] [Abstract][Full Text] [Related]
8. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Safi F; Kohler I; Röttinger E; Suhr P; Beger HG Int J Biol Markers; 1989; 4(4):207-14. PubMed ID: 2628501 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer. Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976 [TBL] [Abstract][Full Text] [Related]
10. Breast cancer marker Ca549. A multicenter study. Chan DW; Beveridge RA; Bhargava A; Wilcox PM; Kennedy MJ; Schwartz MK Am J Clin Pathol; 1994 Apr; 101(4):465-70. PubMed ID: 8160638 [TBL] [Abstract][Full Text] [Related]
11. Serum and immunohistochemical studies of NCC-ST-439 in breast cancer. Narita T; Funahashi H; Satoh Y; Imai T; Takagi H J Surg Oncol; 1993 Sep; 54(1):5-8. PubMed ID: 8377506 [TBL] [Abstract][Full Text] [Related]
12. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer. Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872 [TBL] [Abstract][Full Text] [Related]
13. Circulating CA 549 and other associated antigens in breast cancer patients. Pavesi F; Lotzniker M; Scarabelli M; Mauro E; Visconti G; Nicolato E; Moratti R Oncology; 1994; 51(1):18-21. PubMed ID: 8265097 [TBL] [Abstract][Full Text] [Related]
14. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors. Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573 [TBL] [Abstract][Full Text] [Related]
15. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer]. Kaneko Y; Imoto S; Kasakura S Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542 [TBL] [Abstract][Full Text] [Related]
16. CA549 and TPS patterns in the diagnosis and staging of patients with breast carcinoma. Vibert HG; Houston AS; Wilkins GP; Kemp PM; Macleod MA Int J Biol Markers; 1996; 11(4):198-202. PubMed ID: 9017442 [TBL] [Abstract][Full Text] [Related]
17. A new approach to tumour marker assessment by perioperative determination in breast and colorectal cancer. Gion M; Ruggeri G; Mione R; Marconato R; Casella C; Nosadini A; Simoncini E; Belloli S; Dal Zennaro E; Bruscagnin G Int J Biol Markers; 1993; 8(1):8-13. PubMed ID: 8496629 [TBL] [Abstract][Full Text] [Related]
18. MCA in patients with breast cancer: correlation with CEA and CA15-3. Molina R; Filella X; Mengual P; Prats M; Zanon G; Daniels M; Ballesta AM Int J Biol Markers; 1990; 5(1):14-21. PubMed ID: 2230347 [TBL] [Abstract][Full Text] [Related]
19. Comparison of serum CA15-3 and CEA in breast cancer. Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526 [TBL] [Abstract][Full Text] [Related]
20. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]